Patents Examined by Kenneth A. Sorensen
  • Patent number: 5686597
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel thrombin receptor homolog (TRH) expressed in human liver. The present invention also provides for antisense molecules to the nucleotide sequences which encode TRH, diagnostic tests based on TRH encoding nucleic acid molecules, expression vectors for the production of purified TRH, antibodies capable of binding specifically to TRH, hybridization probes or oligonucleotides for the detection of TRH-encoding nucleotide sequences, genetically engineered host cells for the expression of TRH, and antagonists, antibodies and inhibitors with specific binding activity for the polypeptide TRH.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 11, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Roger Coleman, Janice Au-Young, Olga Bandman, Jeffrey J. Seilhamer
  • Patent number: 5683903
    Abstract: Attachment enhanced human embryonic kidney cells, 293, are provided. These cells have been modified to contain a selected mammalian scavenger gene, which has been found to improve the ability of these cells to attach in culture. The improved cells of the invention are useful in assays in which the unmodified 293 cells could be used.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: November 4, 1997
    Assignee: SmithKline Beecham Corporation
    Inventors: Paul G. Lysko, Nabil A. Elshourbagy, Mary E. Brawner
  • Patent number: 5650504
    Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: July 22, 1997
    Assignee: Amgen Inc.
    Inventors: Timothy D. Bartley, William J. Boyle, Vann P. Parker, Gary M. Fox, Andrew A. Welcher
  • Patent number: 5650293
    Abstract: A substantially pure nucleic acid comprising a sequence encoding a pp60.sup.PIK peptide and methods of using nucleic acid encoding pp60.sup.PIK to make pp60.sup.PIK polypeptide.
    Type: Grant
    Filed: June 10, 1994
    Date of Patent: July 22, 1997
    Assignee: Joslin Diabetes Center, Inc.
    Inventor: Morris F. White
  • Patent number: 5648464
    Abstract: The present invention relates to nucleotide sequences of the human Notch and Delta genes, and amino acid sequences of their encoded proteins, as well as fragments thereof containing an antigenic determinant or which are functionally active. The invention is also directed to fragments (termed herein "adhesive fragments"), and the sequences thereof, of the proteins ("toporythmic proteins") encoded by toporythmic genes which mediate homotypic or heterotypic binding to toporythmic proteins. Toporythmic genes, as used herein, refers to the genes Notch, Delta, and Serrate, as well as other members of the Delta/Serrate family which may be identified, e.g., by the methods described herein. Analogs and derivatives of the adhesive fragments which retain binding activity are also provided. Antibodies to human Notch and to adhesive fragments are additionally provided.
    Type: Grant
    Filed: June 23, 1994
    Date of Patent: July 15, 1997
    Assignee: Yale University
    Inventors: Spyridon Artavanis-Tsakonas, Richard Grant Fehon, Ilaria Rebay, Christine Marie Blaumueller
  • Patent number: 5646030
    Abstract: Disclosed is a method for isolating a mutant cell that excretes a desired compound. The method includes culturing a plurality of auxotrophic pretreated starter cells and auxotrophic feeder cells in the presence of a reversibly noninfective, modified lambdoid bacteriophage. If the treated starter cell produces the desired compound, the bacteriophage will be rendered infective and infect the feeder cell. The feeder cell, in turn, will excrete a metabolite required by the starter cell and the starter cell will excrete a metabolite required by the feeder cell, enabling the cells to cross-feed, grow, and produce a colony containing a starter cell which produces the desired compound.
    Type: Grant
    Filed: August 23, 1994
    Date of Patent: July 8, 1997
    Assignee: President and Fellows of Harvard College
    Inventors: Bryan L. Ray, Edmund C. C. Lin, Roberto Crea
  • Patent number: 5618677
    Abstract: This invention describes a novel human brain Na.sup.+ -dependent inorganic phosphate cotransporter, designated the hBNPI protein. This invention also encompasses nucleic acids encoding this protein, or a fragment thereof, as well as methods employing this protein and the nucleic acid compounds.
    Type: Grant
    Filed: May 14, 1996
    Date of Patent: April 8, 1997
    Assignee: Eli Lilly and Company
    Inventors: Binhui Ni, Steven M. Paul
  • Patent number: 5618918
    Abstract: This invention describes a novel human brain Na.sup.+ -dependent inorganic phosphate cotransporter, designated the hBNPI protein. This invention also encompasses nucleic acids encoding this protein, or a fragment thereof, as well as methods employing this protein and the nucleic acid compounds.
    Type: Grant
    Filed: May 14, 1996
    Date of Patent: April 8, 1997
    Assignee: Eli Lilly and Company
    Inventors: Binhui Ni, Steven M. Paul